- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01075997
The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus
24. februar 2010 opdateret af: Walter Reed Army Medical Center
The purpose of the study is to determine whether having a video cell phone that gives daily reminders over a 6-month period to check blood surgery and take your diabetes medications can improve your diabetes control during that time and if that benefit lasts for up to 1 year.
Studieoversigt
Status
Ukendt
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The purpose of this study is to determine if a cell phone video reminder system will improve compliance and glycemic control in patients with diabetes mellitus when compared with standard of care.
We plan to partner with Affinity Network, Inc., a local minority-owned small business, to provide broadband-enabled cell phone service to patients with diabetes mellitus.
Their IntelaCare™ system will host the content and transmit it to the phones on a personalized schedule.
This will be a prospective, randomized, controlled trial comparing patients with diabetes mellitus who receive daily video reminders via cell phone to take their medications and check their blood glucose with patients who are just given a cell phone without daily reminders.
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
The secondary endpoints will compare mean daily glucose levels, the number of both hypoglycemic and hyperglycemic events, the amount of time spent in target blood glucose, and the perceived level of diabetes-related stress between the two groups.
Patients in both groups will receive a broad-band enabled cell phone and cell phone service for the duration of the study.
Patients will be randomized into a "cell phone" group (group A) and a "cell phone plus reminder" group (group B).
They will be seen by their provider at least quarterly (or more often as clinically appropriate).
Blood glucose readings will be downloaded from patients' glucometers at every provider visit (at least quarterly).
Group B will receive a daily 15-second video from their provider reminding them to take their medication and to test their blood sugar and an educational "tip-of-the day."
These reminders will be personalized and recorded by their provider.
During the second 6 months, the patients will be followed by their provider at least quarterly.
Improvement in glycemic control will be determined by quarterly measurements of A1c and the mean and standard deviation of blood glucose.
In addition, the number of home blood glucose tests performed on a weekly basis will be compared.
Compliance with medication will be determined by pharmacy refill records and pill counts.
Quality-of-life will be measures using 2 validated instruments at 0, 26 and 52 weeks - the Problem Areas in Diabetes (PAID), which is a diabetes-related quality of life questionnaire and the SF-8, which is a general quality of life questionnaire for people with chronic disease.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
170
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
District of Columbia
-
Washington DC, District of Columbia, Forenede Stater, 20307
- Walter Reed Army Hospital Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 89 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- age 18 or greater
- A1c greater than 8%
- ability to use a cell phone and glucose meter
- ability to understand English
- on oral therapy and/or insulin
Exclusion Criteria:
- under age 18
- non-English speaking
- females who are pregnant, lactating, planning to become pregnant, or without a safe contraceptive method
- A1c less than 8%
- use of glucocorticoids, amphetamines, anabolic, or weight-reducing agents during the course of the study
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: A cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
The group will be asked to check blood sugar on a schedule determined by their providers.
The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed.
The group will have the A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
Andre navne:
|
Aktiv komparator: B no cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider.
The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed.
The group will have A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider.
The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
Tidsramme: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.
Tidsramme: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Amanda Bell, MD, WRAMC
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2007
Primær færdiggørelse (Forventet)
1. juli 2010
Studieafslutning (Forventet)
1. oktober 2010
Datoer for studieregistrering
Først indsendt
24. februar 2010
Først indsendt, der opfyldte QC-kriterier
24. februar 2010
Først opslået (Skøn)
25. februar 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
25. februar 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. februar 2010
Sidst verificeret
1. juni 2009
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- WU#07-13025
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsAfsluttetDiabetes mellitus type 2, diabetes mellitus type 1Tyskland